


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
-7.21%
-1.78%
-1.33%
-5.70%
-8.05%
MRK
Merck Company
$96.89
Strengths

Earnings are forecast to grow

Trading below its fair value
Risk Analysis

Investors losing their confidence
MRK Price Performance
$86.75 (+11.69%)
$82.81 (+17.00%)
$81.52 (+18.85%)
$99.52 (-2.64%)
MRK has Low risk level based on volatility, sector strength, volume, investor confidence, and outlook.
Click here to check what is your level of risk

MRK overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings

Above analyst estimates

Eps growth
Rating
Rating
Momentum
Momentum

Has been gaining momentum
Activity
Activity

Investors losing their confidence
Future
Future

Earnings are forecast to grow

Trading below its fair value
![]()
MRK Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential
MRK Street Sentiment is bullish and have positive views on the near-term outlook
Average key support and resistance price levels
Login to displayAZN
89.82
-1.60%
PFE
25.33
-1.78%
NVS
131.01
+0.63%
SNY
47.83
-1.26%
ABBV
222.99
-0.03%
What is MRK current stock price?
What are MRK stock strengths?
What is MRK Risk Level?
What is MRK market cap and volume?
What is MRK current Stock IQ?
Should I buy MRK stock right now?
Is MRK a Strong Buy right now?
What does a 'Strong Buy' rating mean for MRK?
What does a 'Strong Sell' rating mean for MRK?
What factors influence MRK's Stock IQ?
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
-7.21%
-1.78%
-1.33%
-5.70%
-8.05%
MRK
Merck Company
Current Price
$96.89
Stock Insights
Strengths

Earnings are forecast to grow

Trading below its fair value
Risk Analysis

Investors losing their confidence
Linked to MRK
AZN
89.82
-1.60%
PFE
25.33
-1.78%
NVS
131.01
+0.63%
SNY
47.83
-1.26%
ABBV
222.99
-0.03%

MRK Price Performance
$86.75 (+11.69%)
$82.81 (+17.00%)
$81.52 (+18.85%)
$99.52 (-2.64%)
MRK Analysts Opinion
MRK Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings

Above analyst estimates

Eps growth
Rating
Rating
Momentum
Momentum

Has been gaining momentum
Activity
Activity

Investors losing their confidence
Future
Future

Earnings are forecast to grow

Trading below its fair value
![]()
MRK Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential
MRK Street Sentiment is bullish and have positive views on the near-term outlook
MRK has Low risk level based on volatility, sector strength, volume, investor confidence, and outlook.
Click here to check what is your level of risk

Average key support and resistance price levels
MRK Stock IQ
MRK Latest Analysis
Heres 1 Major Catalyst Behind Merck Stocks Recent 3.8% Bump. Key PointsMerck spent a small fortune on the acquisition of Acceleron Pharma and so far its paying off.
Today
MRK Stock Trading Above 200- & 50-Day SMA for 2 Months: Time to Buy?. Merck holds ish momentum as pipeline advances and major deals offset vaccine weakness and Keytruda risks.
Today
FDA approves Merck drug for decimated United States cattle herds to stop screwworm. Theres hope for United States cattle ranchers in the battle to stop the spread of screwworm at a time of decimated herds with the FDA approving a new Merck treatment.
Today
MRK Quantitative Stock Analysis - Peter Lynch. Below is Valideas guru fundamental report for MERCK &. CO INC (MRK). Of the 22 guru strategies we follow MRK rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. This strategy looks for stocks trading at a reasonable price relati
Today
Is This Pharmaceutical Giant a Buy After a Major Acquisition?. Key PointsMercks newest acquisition could help it launch a promising flu candidate.
Fri Dec 5, 2025
Peter Lynch Detailed Fundamental Analysis - MRK. Below is Valideas guru fundamental report for MERCK &. CO INC (MRK). Of the 22 guru strategies we follow MRK rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. This strategy looks for stocks trading at a reasonable price relati
Fri Dec 5, 2025
Merck Unit Gets FDA Conditional Approval For EXZOLT CATTLE-CA1 To Treat Key Cattle Parasites . (RTTNews) - Merck Animal Health a division of Merck & Co. Inc.(MRK) announced that the United States Food and Drug Administration has granted conditional approval for EXZOLT CATTLE-CA1 (fluralaner topical solution).
Fri Dec 5, 2025
Can Mercks New Products Aid Growth as Keytruda LOE Test Looms?. MRK banks on Capvaxive Winrevair and other new launches to counter Keytrudas looming 2028 LOE and record long-term growth.
Thu Dec 4, 2025
Pliant Cancer Drug Boosts Responses When Paired With Mercks Blockbuster Keytruda In Tough-To-Treat Tumors. ) is capturing attention with promising trial results for its cancer therapy despite a sharp stock decline.PLRX stock is showing notable weakness. Pliant Therapeutics on Thursday released interim data from its Phase 1 dose .The trial evaluated PLN-101095 in combination with ) Keytruda (pembrolizumab) in patients with immune checkpoint inhibitor (ICI)-refractory .PLN-101095 is the fourth cli
Thu Dec 4, 2025
Guru Fundamental Report for MRK - Peter Lynch. Below is Valideas guru fundamental report for MERCK &. CO INC (MRK). Of the 22 guru strategies we follow MRK rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. This strategy looks for stocks trading at a reasonable price relati
Thu Dec 4, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.